Study of Guselkumab Use and Treatment Continuation in Adults with Moderate to Severe Crohns Disease or Ulcerative Colitis

What this Trial Is About

Researchers are studying how long people with moderate to severe Crohns disease or ulcerative colitis continue using guselkumab treatment in real-world settings. These conditions are types of inflammatory bowel diseases affecting the colon and small intestine. The study aims to understand treatment persistence without providing the medication as part of the trial. Participants who have a confirmed diagnosis of moderate to severe Crohns disease or ulcerative colitis and are starting guselkumab as part of their normal care will be included. No study drug is given by the research team instead, data from routine clinical practice and medical records will be collected over time. The study will observe patients up to 96 weeks to assess treatment patterns and responses. During the study, participants medical records will be reviewed for clinical responses, remission rates, medication use, adverse events, and quality of life measures at various times up to 96 weeks. Researchers will track bowel urgency, clinical scores, lab markers, and endoscopic findings to evaluate treatment effects. Safety events and healthcare use such as hospitalizations and surgeries will also be recorded. Overall participation lasts up to about two years, with no extra treatments administered by the study team.

A Study of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis